A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura

Correspondence to Jae Lyun Lee, M.D., Ph.D. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea Tel: +82-2-3010-3210, Fax: +82-2-3010-6961, E-mail: jaelyun@amc.seoul.kr Copyrightc 2013 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Sunitinib 투여로 유발된 혈전성 혈소판 감소성 자반증 1예

[1]  J. Merchan,et al.  Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. , 2012, American journal of therapeutics.

[2]  H. Lim,et al.  TTP-HUS associated with sunitinib. , 2008, Cancer research and treatment : official journal of Korean Cancer Association.

[3]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[4]  G. Lippi,et al.  Reduced von Willebrand Factor-Cleaving Protease Levels in Secondary Thrombotic Microangiopathies and Other Diseases , 2007, Seminars in thrombosis and hemostasis.

[5]  H. Gelderblom,et al.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  D. Nochy,et al.  Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. , 2007, The Lancet. Oncology.

[7]  S. Vesely,et al.  The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency , 2005, Journal of thrombosis and haemostasis : JTH.

[8]  J. George,et al.  Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome , 2001, Current opinion in hematology.

[9]  K. Syrigos,et al.  Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. , 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[10]  C. Nzerue.  Thrombotic microangiopathies. , 2002, The New England journal of medicine.